{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:13:53Z","timestamp":1792113233381,"version":"4.4.0"},"reference-count":240,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejca.2023.113343","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T12:17:33Z","timestamp":1695039453000},"page":"113343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"special_numbering":"C","title":["EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2023"],"prefix":"10.1016","volume":"195","author":[{"given":"Johanna","family":"Latzka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9432","authenticated-orcid":false,"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cozzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-8735","authenticated-orcid":false,"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-8300","authenticated-orcid":false,"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-436X","authenticated-orcid":false,"given":"Constanze","family":"Jonak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Detlev","family":"Klemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-7062","authenticated-orcid":false,"given":"Robert","family":"Knobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morrris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamari","family":"Ranki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4828-1553","authenticated-orcid":false,"given":"Liisa","family":"V\u00e4kev\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8233-938X","authenticated-orcid":false,"given":"Franz","family":"Trautinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113343_bib1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113343_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2023.113343_bib5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-Cell lymphoma in the US from 2000 to 2018: a SEER population data analysis","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2022.104108","article-title":"Recent advances on cutaneous lymphoma epidemiology","volume":"51","author":"Dobos","year":"2022","journal-title":"Presse Med"},{"key":"10.1016\/j.ejca.2023.113343_bib7","first-page":"993","article-title":"Epidemiology of cutaneous lymphoma","volume":"184","author":"Vermeer","year":"2021","journal-title":"Br\u00a0J\u00a0Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib8","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejca.2023.113343_bib10","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113343_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113343_bib14","unstructured":"Primary Cutaneous Lymphoma, Version 1.2023. NCCN clinical practice guidelines in oncology, national comprehensive cancer network, 2023. Retrieved March 2023 from \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf\u3009."},{"key":"10.1016\/j.ejca.2023.113343_bib15","first-page":"537","article-title":"S2k-guidelines - cutaneous lymphomas (ICD10 C82 - C86): update 2021","volume":"20","author":"Dippel","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2023.113343_bib16","unstructured":"OCEBM Levels of Evidence Working Groups. \u2018The Oxford 2011 levels of evidence.\u2019\u00a0Centre for evidence-based medicine. Retrieved March 2023, from \u3008https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence\u3009."},{"key":"10.1016\/j.ejca.2023.113343_bib17","unstructured":"Holwick\u00a0J,\u00a0Chalmers\u00a0I,\u00a0Glasziou\u00a0P,\u00a0Greenhalgh\u00a0T,\u00a0Heneghan\u00a0C,\u00a0Liberati\u00a0A.\u00a0et al. \u2018The 2011 Oxford CEBM levels of evidence (introductory document)\u2019. Oxford centre for evidence-based medicine. Retrieved March 2023, from \u3008https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence\u3009."},{"key":"10.1016\/j.ejca.2023.113343_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jid.2019.07.712","article-title":"Overall survival in mycosis fungoides: a systematic review and meta-analysis","volume":"140","author":"Mourad","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib19","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib22","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib23","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1067\/mjd.2001.117722","article-title":"A modified staging classification for cutaneous T-cell lymphoma","volume":"45","author":"Kashani-Sabet","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.19252","article-title":"Treatment of early-stage mycosis fungoides: results from the PROspective cutaneous lymphoma international prognostic index (PROCLIPI) study","volume":"184","author":"Quaglino","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib27","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaad.2020.05.043","article-title":"Response to topical corticosteroid monotherapy in mycosis fungoides","volume":"84","author":"Kartan","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113343_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjd.12620","article-title":"Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study","volume":"170","author":"Lindahl","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","article-title":"Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis","volume":"27","author":"Lindahl","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/17512433.2014.944500","article-title":"Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma","volume":"7","author":"Talpur","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ejca.2023.113343_bib35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjd.12890","article-title":"Nitrogen mustard revisited","volume":"170","author":"Knobler","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clml.2020.11.022","article-title":"Evaluating the treatment patterns of chlormethine\/mechlorethamine gel in patients with stage I-IIA mycosis fungoides: by-time reanalysis of a randomized controlled phase 2 study","volume":"21","author":"Geskin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2023.113343_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000516138","article-title":"Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides","volume":"238","author":"Querfeld","year":"2022","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.ejca.2023.113343_bib38","first-page":"579","article-title":"The optimal use of chlormethine gel for mycosis fungoides: an expert consensus from Germany, Austria and Switzerland (DACH region)","volume":"20","author":"Assaf","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2023.113343_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe Study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib40","first-page":"1","article-title":"Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects","author":"Prag Naveh","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ejca.2023.113343_bib41","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1007\/s12325-021-01721-x","article-title":"Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T cell lymphoma: three case reports","volume":"38","author":"Lampadaki","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib42","article-title":"A little experience goes a long way: chlormethine\/mechlorethamine treatment duration as a function of clinician-level patient volume for mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)-a retrospective cohort study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejca.2023.113343_bib43","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1095","article-title":"Chlormethine gel is efficient and safe in mycosis fungoides skin lesions","volume":"102","author":"Koumourtzis","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s13555-022-00681-6","article-title":"Randomized mechlorethamine\/chlormethine induced dermatitis assessment study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides","volume":"12","author":"Alexander-Savino","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ejca.2023.113343_bib45","first-page":"1057","article-title":"Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers","volume":"19","author":"Wehkamp","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2023.113343_bib46","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","article-title":"Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience","volume":"11","author":"Geskin","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ejca.2023.113343_bib47","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","article-title":"Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study","volume":"83","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib48","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/jdv.18183","article-title":"Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice","volume":"36","author":"Papadavid","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib49","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jid.2020.12.009","article-title":"Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"141","author":"Querfeld","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib50","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1203475415626686","article-title":"Tazarotene 0.1% cream as monotherapy for early-stage cutaneous T-cell lymphoma","volume":"20","author":"Besner Morin","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ejca.2023.113343_bib51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2003.09.005","article-title":"Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study","volume":"50","author":"Apisarnthanarax","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib52","first-page":"906","article-title":"Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%","volume":"5","author":"Rallis","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib53","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1016\/S2352-3026(22)00107-7","article-title":"Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial","volume":"9","author":"Ortiz-Romero","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2023.113343_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13555-019-00317-2","article-title":"Revisiting imiquimod for treatment of folliculotropic mycosis fungoides: a case report and review of the literature","volume":"9","author":"Shalabi","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ejca.2023.113343_bib55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","article-title":"Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series","volume":"28","author":"Lewis","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ejca.2023.113343_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2004.04.049","article-title":"Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream","volume":"52","author":"Deeths","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib57","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib58","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archderm.139.5.624","article-title":"Phase 1\/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides","volume":"139","author":"Demierre","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib59","first-page":"1017","article-title":"Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil","volume":"9","author":"Kannangara","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib60","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1067\/mjd.2001.113478","article-title":"A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma","volume":"44","author":"Duvic","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib61","article-title":"Quality of life, anxiety, and depression in patients with early-stage mycosis fungoides and the effect of oral psoralen plus UV-A (PUVA) photochemotherapy on it","volume":"7","author":"Graier","year":"2020","journal-title":"Front Med ((Lausanne))"},{"key":"10.1016\/j.ejca.2023.113343_bib62","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1111\/jdv.16283","article-title":"Impact of narrow-band ultraviolet B phototherapy on remission and relapses of mycosis fungoides in patients with Fitzpatrick skin III-IV","volume":"34","author":"Huang","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib63","doi-asserted-by":"crossref","first-page":"251","DOI":"10.15171\/jlms.2019.40","article-title":"Successful use of the 308-nm excimer laser in early patch stage mycosis fungoides","volume":"10","author":"Armenta","year":"2019","journal-title":"J Lasers Med Sci"},{"key":"10.1016\/j.ejca.2023.113343_bib64","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1684\/ejd.2021.4085","article-title":"Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides","volume":"31","author":"Furukawa","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5021\/ad.2018.30.1.93","article-title":"Hypopigmented mycosis fungoides treated with 308 nm excimer laser","volume":"30","author":"Yang","year":"2018","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.23736\/S0392-0488.18.05867-4","article-title":"Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1","volume":"155","author":"Trovato","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib67","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000458149","article-title":"Ultraviolet A1 phototherapy in the treatment of early mycosis fungoides","volume":"233","author":"Ad\u0131\u015fen","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2023.113343_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib69","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archderm.135.11.1377","article-title":"Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides","volume":"135","author":"Hofer","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib70","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamadermatol.2018.5204","article-title":"Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis","volume":"155","author":"Phan","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/phpp.12383","article-title":"Phototherapy as a first-line treatment for early-stage mycosis fungoides: the results of a large retrospective analysis","volume":"34","author":"Nikolaou","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.ejca.2023.113343_bib72","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaad.2018.05.023","article-title":"Potential of narrow-band ultraviolet B to induce sustained durable complete remission off-therapy in patients with stage I mycosis fungoides","volume":"80","author":"Pavlotsky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib73","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.clml.2017.06.015","article-title":"Bath psoralen-ultraviolet A and narrowband ultraviolet B phototherapy as initial therapy for early-stage mycosis fungoides: a retrospective cohort of 267 cases at the University of Toronto","volume":"17","author":"Almohideb","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2023.113343_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1346-8138.16077","article-title":"Efficacy of bath-psoralen and ultraviolet A therapy for mycosis fungoides - retrospective analysis of 62 cases","volume":"49","author":"Shintani","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15418","article-title":"Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: a systematic review and meta-analysis","author":"Ginsburg","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study","volume":"66","author":"Stern","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2023.113343_bib77","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib78","article-title":"Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma","volume":"11","author":"Jones","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.113343_bib79","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2020009655","article-title":"Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib80","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-0781.2011.00559.x","article-title":"Phototherapy of mycosis fungoides","volume":"27","author":"Trautinger","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.ejca.2023.113343_bib81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaad.2008.08.043","article-title":"Phototherapy for cutaneous T-cell lymphoma: online survey and literature review","volume":"60","author":"Carter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib83","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/phpp.12698","article-title":"Photodynamic therapy of mycosis fungoides: a systematic review of case studies","volume":"37","author":"Hooper","year":"2021","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.ejca.2023.113343_bib84","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jaad.2021.01.053","article-title":"Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: a prospective, open-label study","volume":"85","author":"Severson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib85","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma project group","volume":"47","author":"Jones","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib86","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0889-8588(03)00108-4","article-title":"Total skin electron beam radiotherapy for patients who have mycosis fungoides","volume":"17","author":"Jones","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2023.113343_bib87","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low-dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib88","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib89","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib90","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000475634","article-title":"Total skin electron beam therapy as part of multimodal treatment strategies for primary cutaneous T-cell lymphoma","volume":"40","author":"Elsayad","year":"2017","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ejca.2023.113343_bib91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0167-8140(99)00162-0","article-title":"Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation","volume":"54","author":"Maingon","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib92","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0360-3016(91)90028-3","article-title":"Total skin electron beam and total nodal irradiation of cutaneous T-cell lymphoma","volume":"20","author":"Micaily","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaad.2020.12.023","article-title":"Prospective observational trial of low-dose skin electron beam therapy in mycosis fungoides using a rotational technique","volume":"85","author":"Newman","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib94","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00066-019-01517-7","article-title":"Low-dose total skin electron beam therapy: quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome","volume":"196","author":"Elsayad","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113343_bib95","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2023.02.052","article-title":"Ultrahypofractionated low-dose total skin electron beam in advanced-stage mycosis fungoides and S\u00e9zary syndrome","volume":"117","author":"Elsayad","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib96","first-page":"77","article-title":"Total skin electron beam therapy for cutaneous T-cell lymphomas in the Netherlands: a retrospective analysis of treatment outcomes and selection for high or low dose schedule","volume":"33","author":"Smits","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib97","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ijrobp.2017.05.052","article-title":"The results of low-dose total skin electron beam radiation therapy (TSEB) in patients with mycosis fungoides from the UK cutaneous lymphoma group","volume":"99","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib98","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2020.01.046","article-title":"A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life","volume":"83","author":"Song","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib99","first-page":"26","article-title":"Clinical application of total skin electron beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12\u00a0Gy) treatment schedule","volume":"15","author":"Georgakopoulos","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib100","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1080\/10428194.2019.1574008","article-title":"Comparison of low-dose and standard-dose total skin electron beam therapy in mycosis fungoides","volume":"60","author":"Dault","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2023.113343_bib101","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2340\/00015555-3124","article-title":"Low- versus middle-dose total skin electron beam therapy for mycosis fungoides: an efficiency-based retrospective survey of skin response","volume":"99","author":"Taverniers","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib102","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clon.2018.06.006","article-title":"Total skin electron irradiation and sequential malignancies in mycosis fungoides patients: longitudinal study","volume":"30","author":"Lutsyk","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ejca.2023.113343_bib103","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2018.12.003","article-title":"Multi-institutional investigation: circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides","volume":"131","author":"An","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamadermatol.2020.3958","article-title":"Low-dose total skin electron beam therapy as part of a multimodality regimen for treatment of S\u00e9zary syndrome: clinical, immunologic, and molecular analysis","volume":"157","author":"Durgin","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2007.12.016","article-title":"Total skin electron beam therapy may be associated with improvement of peripheral blood disease in S\u00e9zary syndrome","volume":"58","author":"Introcaso","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib106","article-title":"Low-dose total skin electron beam therapy combined with mogamulizumab for refractory mycosis fungoides and S\u00e9zary syndrome","volume":"6","author":"Fong","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib107","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2018.07.040","article-title":"Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: a comparative decision analysis model in the United States","volume":"80","author":"Xia","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib108","doi-asserted-by":"crossref","first-page":"483","DOI":"10.23736\/S0392-0488.18.05914-X","article-title":"Results of radiotherapy in minimal stage mycosis fungoides: a reappraisal after ten years","volume":"155","author":"Esposito","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib109","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2012.05.034","article-title":"Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma","volume":"85","author":"Thomas","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib110","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1365-2133.2011.10728.x","article-title":"Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas","volume":"166","author":"Chan","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib111","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides-a dose response.","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib112","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","article-title":"Radiotherapy for unilesional mycosis fungoides","volume":"42","author":"Micaily","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113343_bib113","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaad.2012.12.975","article-title":"Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma","volume":"69","author":"DeSimone","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib114","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/j.clml.2018.04.010","article-title":"Treatment of vulvar mycosis fungoides tumors with localized radiotherapy","volume":"18","author":"Geller","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2023.113343_bib115","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-18-4147","article-title":"Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides","volume":"26","author":"O'Malley","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2023.113343_bib116","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful end-point for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.113343_bib117","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000512484","article-title":"Evaluation of alitretinoin for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"237","author":"Alhusayen","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2023.113343_bib118","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1002\/cam4.4237","article-title":"Alitretinoin in the treatment of cutaneous T-cell lymphoma","volume":"10","author":"Kaemmerer","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.113343_bib119","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/09546634.2018.1487525","article-title":"Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work?","volume":"30","author":"Amitay-Laish","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ejca.2023.113343_bib120","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/jdv.16567","article-title":"Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study","volume":"34","author":"Nikolaou","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib121","series-title":"Retinoids e advances in basic research and therapy","first-page":"313e6","article-title":"Treatment of parapsoriasis en plaques and mycosis fungoides with an oral aromatic retinoid (Ro 10-9359)","author":"Souteyrand","year":"1981"},{"key":"10.1016\/j.ejca.2023.113343_bib122","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","article-title":"Treatment of cutaneous T-cell lymphoma with retinoids","volume":"19","author":"Zhang","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib123","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jdv.12684","article-title":"Treatment of cutaneous T-cell lymphoma with oral alitretinoin","volume":"29","author":"Kapser","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib124","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2217\/imt.13.15","article-title":"Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides","volume":"5","author":"Pileri","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejca.2023.113343_bib125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib126","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib127","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1346-8138.13542","article-title":"Phase I\/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas","volume":"44","author":"Hamada","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/1346-8138.14923","article-title":"Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: the results of a phase 2 study (B-1201)","volume":"46","author":"Hamada","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland","volume":"92","author":"V\u00e4kev\u00e4","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib131","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib132","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/1346-8138.16201","article-title":"Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: real-world experience from post-marketing surveillance","volume":"49","author":"Hamada","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib133","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/1346-8138.15310","article-title":"Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma","volume":"47","author":"Morita","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib134","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14805","article-title":"A case of mycosis fungoides successfully treated with combination of bexarotene and mogamulizumab","volume":"34","author":"Hisamoto","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib135","first-page":"279","article-title":"Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma","volume":"20","author":"Elsayad","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2023.113343_bib136","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib137","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1111\/jdv.17795","article-title":"The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides","volume":"36","author":"Patsatsi","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib138","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/jdv.14366","article-title":"Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma","volume":"31","author":"Schiller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib139","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2005.04.3216","article-title":"Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma","volume":"24","author":"Dummer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib140","first-page":"29","article-title":"Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas","volume":"18","author":"Loquai","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib141","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/annonc\/mdw225","article-title":"Adjuvant treatment with pegylated interferon \u03b1-2a versus low-dose interferon \u03b1-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial","volume":"27","author":"Eigentler","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib142","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10401230701333038","article-title":"Neuropsychiatric complications of interferons: classification, neurochemical bases, and management","volume":"19","author":"Malek-Ahmadi","year":"2007","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.ejca.2023.113343_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and Hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2023.113343_bib144","first-page":"283","article-title":"Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database","volume":"9","author":"Sato","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib145","doi-asserted-by":"crossref","first-page":"349","DOI":"10.36849\/JDD.5756","article-title":"Clinical trial of high-dose pegylated-interferon-alfa-2b combined with phototherapy in advanced stage mycosis fungoides","volume":"20","author":"Walker","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib146","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s13555-022-00831-w","article-title":"Maintenance and concomitant therapy use with chlormethine gel among patients with stage IA\/IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study","volume":"12","author":"Querfeld","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ejca.2023.113343_bib147","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1111\/jdv.18691","article-title":"Bendamustine monochemotherapy in aggressive or advanced-stage primary cutaneous T-cell lymphomas","volume":"37","author":"Michalowitz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib148","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjd.20757","article-title":"Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides","volume":"186","author":"Falkenhain-L\u00f3pez","year":"2022","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113343_bib149","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/ced.15224","article-title":"Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas","volume":"47","author":"Falkenhain-L\u00f3pez","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib150","first-page":"1","article-title":"Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment: real-life data from the German cutaneous lymphoma network","author":"Blazejak","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2023.113343_bib151","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15482","article-title":"Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study","author":"Di Raimondo","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib152","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1684\/ejd.2018.3444","article-title":"Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory S\u00e9zary syndrome: a systematic review.","volume":"28","author":"Stewart","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib153","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2040620716636541","article-title":"Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential","volume":"7","author":"Duvic","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ejca.2023.113343_bib154","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib155","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jdv.17523","article-title":"Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial","volume":"35","author":"Cowan","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib156","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1080\/10428194.2021.1953007","article-title":"Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial","volume":"62","author":"Horwitz","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2023.113343_bib157","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-19-2742","article-title":"Mogamulizumab forecast: clearer patients, with a slight chance of immune mayhem","volume":"25","author":"Larocca","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113343_bib158","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"de Masson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib159","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-021-00624-7","article-title":"Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: characterization and management","volume":"12","author":"Musiek","year":"2022","journal-title":"Dermatol Ther ((Heidelb))"},{"key":"10.1016\/j.ejca.2023.113343_bib160","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib161","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113343_bib162","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin versus physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2023.113343_bib163","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib164","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous t-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib165","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S\u00e9zary syndrome with variable CD30 positivity","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib166","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/bjd.17726","article-title":"Brentuximab vedotin: unexpectedly good response in CD30(-) mycosis fungoides","volume":"180","author":"Sun","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib167","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamadermatol.2017.3961","article-title":"Treatment of CD30-negative refractory mycosis fungoides with brentuximab vedotin","volume":"154","author":"Zhang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib168","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12835","article-title":"Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin","volume":"32","author":"Goyal","year":"2019","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.ejca.2023.113343_bib169","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/his.14660","article-title":"Intraindividual variability of CD30 expression in mycosis fungoides -implications for diagnostic evaluation and therapy","volume":"81","author":"Mitteldorf","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2023.113343_bib170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib171","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib172","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.733770","article-title":"Immune check point inhibitors in primary cutaneous T-cell lymphomas: biologic rationale, clinical results and future perspectives","volume":"11","author":"Roccuzzo","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.113343_bib173","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164793","article-title":"Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment","volume":"8","author":"Gao","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejca.2023.113343_bib174","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-Cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113343_bib175","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26974-6","article-title":"Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma","volume":"12","author":"Phillips","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2023.113343_bib176","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1738797","article-title":"Blockade of programmed cell death protein 1 (PD-1) in S\u00e9zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation","volume":"9","author":"Saulite","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2023.113343_bib177","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood-2017-06-792382","article-title":"KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting","volume":"130","author":"Battistella","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib178","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib179","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/jdv.16890","article-title":"European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1","volume":"34","author":"Knobler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09546634.2019.1587144","article-title":"Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015","volume":"31","author":"Ling","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ejca.2023.113343_bib181","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/bjd.15871","article-title":"UK national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma","volume":"178","author":"Sanyal","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib182","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jca.21933","article-title":"Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: real-life experience in Argentina","volume":"36","author":"Baquero Rey","year":"2021","journal-title":"J Clin Apher"},{"key":"10.1016\/j.ejca.2023.113343_bib183","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with S\u00e9zary syndrome","volume":"134","author":"Gao","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib184","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.det.2015.05.011","article-title":"Extracorporeal photopheresis in the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"33","author":"Zic","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ejca.2023.113343_bib185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2011.03.003","article-title":"Multicenter photopheresis intervention trial in early-stage mycosis fungoides","volume":"11","author":"Talpur","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2023.113343_bib186","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib187","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2023.113343_bib188","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib189","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bmt.2011.201","article-title":"Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas","volume":"47","author":"Paralkar","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2023.113343_bib190","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.clml.2014.09.013","article-title":"Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with S\u00e9zary syndrome","volume":"15","author":"Polansky","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2023.113343_bib191","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hon.2162","article-title":"Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome","volume":"34","author":"Shiratori","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib192","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2023.113343_bib193","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2023.113343_bib194","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib195","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15447","article-title":"Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome","author":"Cengiz Seval","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib196","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hon.2719","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and S\u00e9zary syndrome","volume":"38","author":"Mori","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib197","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"56","author":"Domingo-Domenech","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2023.113343_bib198","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1080\/10428194.2020.1790555","article-title":"Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas","volume":"61","author":"Isufi","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2023.113343_bib199","article-title":"Long-term disease control after allogeneic hematopoietic stem cell transplantation in primary cutaneous T-cell lymphoma; results from a single institution analysis","volume":"7","author":"Dimitriou","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejca.2023.113343_bib200","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjd.18541","article-title":"Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T-cell lymphoma at a tertiary care centre: should we avoid chemotherapy in conditioning regimes?","volume":"182","author":"Ritchie","year":"2020","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.ejca.2023.113343_bib201","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.3390\/cancers12102856","article-title":"Allogeneic hematopoietic stem cell transplantation in cutaneous T-Cell lymphomas","volume":"12","author":"Dumont","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.113343_bib202","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2019.08.019","article-title":"Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis","volume":"26","author":"Iqbal","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10392","key":"10.1016\/j.ejca.2023.113343_bib203","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113343_bib204","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bjd.15302","article-title":"Maintenance phase in psoralen-ultraviolet a phototherapy of early-stage mycosis fungoides. A critically appraised topic","volume":"177","author":"Grandi","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2020.10.007","article-title":"Maintenance therapy in patients with mycosis fungoides or S\u00e9zary syndrome: a neglected topic","volume":"142","author":"Stadler","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113343_bib206","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/jamadermatol.2018.5905","article-title":"Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: a randomized clinical trial","volume":"155","author":"Vieyra-Garcia","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.ejca.2023.113343_bib207","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clml.2022.02.002","article-title":"Response to chlormethine\/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single-center retrospective study","volume":"22","author":"Correia","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2023.113343_bib208","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/cco.2018.10.01","article-title":"Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment","volume":"8","author":"Jennings","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113343_bib209","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1684\/ejd.2017.3008","article-title":"A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs","volume":"27","author":"Bagot","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib210","unstructured":"Mycosis Fungoides\/Sezary Syndrome, Version 2021. NCCN guidelines for patients, national comprehensive cancer network, 2021. Retrieved March 2023 from \u3008https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/nhl-mycosis-patient.pdf\u3009."},{"key":"10.1016\/j.ejca.2023.113343_bib211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","article-title":"Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator","volume":"9","author":"Ottevanger","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.ejca.2023.113343_bib212","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/bjd.18089","article-title":"Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study","volume":"182","author":"Molloy","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib213","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2340\/00015555-3171","article-title":"Health-related quality of life in cutaneous lymphomas: past, present and future","volume":"99","author":"Jonak","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib214","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1751561","article-title":"Staphylococcus aureus alpha-toxin inhibits CD8(+) T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma","volume":"9","author":"Bl\u00fcmel","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2023.113343_bib215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00403-019-02015-7","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients","volume":"312","author":"Emge","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ejca.2023.113343_bib216","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V89.1.32.32_32_40","article-title":"Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion","volume":"89","author":"Jackow","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib217","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113343_bib218","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and S\u00e9zary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib219","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-4632.2011.05188.x","article-title":"Prevalence and severity of pruritus in cutaneous T cell lymphoma","volume":"51","author":"Vij","year":"2012","journal-title":"Int J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2023.113343_bib220","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0959-8049(21)00680-8","article-title":"EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and S\u00e9zary syndrome: real-world data in Spanish patients (MICADOS study)","volume":"156","author":"Del Mar Onteniente Gomis","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113343_bib221","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0190-9622(96)90524-1","article-title":"High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings","volume":"35","author":"Yosipovitch","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib222","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamadermatol.2018.2510","article-title":"Aprepitant for the treatment of pruritus in S\u00e9zary Syndrome: a randomized crossover clinical trial","volume":"154","author":"Zic","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib223","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib224","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dth.12113","article-title":"Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant","volume":"27","author":"Jim\u00e9nez Gallo","year":"2014","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113343_bib225","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3194-8","article-title":"Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature","volume":"17","author":"Song","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113343_bib226","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaad.2006.04.025","article-title":"Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma","volume":"55","author":"Demierre","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib227","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1995.tb02485.x","article-title":"Cutaneous colonization with staphylococci influences the disease activity of S\u00e9zary syndrome: a potential role for bacterial superantigens","volume":"133","author":"Tokura","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib228","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/ijd.13832","article-title":"The \u2018Duvic regimen\u2019\u00a0for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and S\u00e9zary syndrome","volume":"57","author":"Lewis","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib229","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdv.15236","article-title":"Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of 174 patients","volume":"33","author":"Lebowitz","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113343_bib230","unstructured":"Methotrexate Containing Medical Products. European medicines agency, retrieved March 2023 from \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/methotrexate-containing-medicinal-products\u3009."},{"key":"10.1016\/j.ejca.2023.113343_bib231","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/S\u00e9zary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib232","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40257-015-0155-3","article-title":"Second primary malignancies in CTCL patients from 1992 to 2011: a SEER-based, population-based study evaluating time from CTCL diagnosis, age, sex, stage, and CD30+ subtype","volume":"17","author":"Amber","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib233","unstructured":"Older Adult Oncology, Version 1.2023. NCCN clincal practice guidelines in oncology, national comprehensive cancer network, retrieved March 2023 from \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/senior.pdf\u3009."},{"key":"10.1016\/j.ejca.2023.113343_bib234","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ejca.2010.02.022","article-title":"EORTC elderly task force position paper: approach to the older cancer patient","volume":"46","author":"Pallis","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113343_bib235","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamadermatol.2016.1597","article-title":"Clinical staging and prognostic factors in folliculotropic mycosis fungoides","volume":"152","author":"van Santen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib236","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaad.2016.03.009","article-title":"New insights into folliculotropic mycosis fungoides (FMF): a single-center experience","volume":"75","author":"Hodak","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113343_bib237","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejca.2023.113343_bib238","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"issue":"11","key":"10.1016\/j.ejca.2023.113343_bib239","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2023.113343_bib240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:01Z","timestamp":1760733721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923006457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":240,"alternative-id":["S0959804923006457"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113343","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2023","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113343"}}